UroCCR Database: French Research Network for Kidney Cancer -UroCCR (UroCCR)

May 27, 2026 updated by: University Hospital, Bordeaux

UroCCR Database: French Research Network for Kidney Cancer (National Multidisciplinary Clinical and Biological Database on Kidney Cancer)

Kidney cancer management has become increasingly complex with the diversification of treatment options and the integration of multidisciplinary care. To meet these challenges, the UroCCR network was established in France as a national registry and research platform dedicated to renal cancer. Funded by the French National Cancer Institute (INCa), UroCCR prospectively collects comprehensive real-world data on patient care and disease evolution, while systematically linking these records with annotated biological samples (plasma, urine, and both healthy and tumour tissues). For each case, more than one thousand variables may be recorded, covering clinical, imaging, and patient-reported information.

More than a registry, UroCCR is a collaborative network of clinical and research professionals using a shared, evolving tool that supports rapid implementation of studies and fosters active knowledge generation. Unlike retrospective registries or sample-centred biobanks, UroCCR offers prospective, patient-focused inclusion and a wide scope of investigation-from translational and technological research to clinical evaluation and social sciences. It also supports multiple ancillary studies, including retrospective analyses and prospective clinical or observational trials, and operates under a structured governance system with recognised national and international labels.

By combining a rigorously structured, multicentre dataset with linkage to the French national health data system (SNDS), the platform uniquely unites detailed clinical annotation with population-wide coverage, creating a high-value environment for advancing kidney cancer research and care.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

The UroCCR project is a national kidney cancer registry and research network designed to address the specific challenges of renal cell carcinoma (RCC) management. While general cancer registries such as FRANCIM provide valuable surveillance data, most large-scale registries lack the depth of clinical, biological, and longitudinal follow-up information necessary to advance research and enable comprehensive analyses of kidney cancer outcomes. UroCCR was created in 2011 to meet this need.

With over 21,000 cases collected from 58 centres across France, UroCCR is now one of the largest national databases dedicated to kidney cancer worldwide. The registry captures detailed clinical parameters, treatments and outcomes, complemented by patient-reported measures and socioeconomic data. Because management practices within UroCCR follow the recommendations of the French Association of Urology (AFU), the dataset closely reflects real-world practice and provides a reliable basis for comparison with national and European guidelines. Moreover, patient data can be reused across numerous studies, allowing researchers to explore multiple scientific questions without requiring new enrolments for each project.

A distinctive strength of UroCCR is its integration of multiple research dimensions. Beyond clinical outcomes, it evaluates quality of life and the social and economic impact of kidney cancer. The registry is linked to annotated biobanking and national medico-administrative datasets, enabling translational studies and health services research. Additionally, UroCCR supports multiple ancillary studies, both retrospective analyses based on real-world data and prospective studies including randomised clinical trials or observational cohorts.

The project benefits from robust governance structures, ensuring standardised procedures, data quality, and ethical oversight. It has also received various national and international labels, recognising its methodological rigour and excellence in research infrastructure.

Digital innovations developed within the network, such as UroConnect® for perioperative monitoring and UroPredict machine learning models for recurrence and survival prediction, highlight its commitment to advancing care through new technologies.

At the national level, projects such as CARARE are developing personalised treatment strategies, including a molecular tumour board for non-clear cell RCC. Internationally, UroCCR is strengthening collaboration through partnerships with the European Association of Urology and the European Robotic Urology Section, contributing to harmonised data collection and large-scale multicentre research.

Ultimately, UroCCR functions as a dynamic research platform that unites clinicians, researchers, and patients around a shared infrastructure. By combining detailed clinical data with translational research, digital health tools, structured governance, recognised labels, and international partnerships, it aims to generate increasingly precise insights into RCC and to support the development of more effective, personalised treatment strategies in France and worldwide.

Study Type

Observational

Enrollment (Estimated)

30000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Belgium
      • Brussels, Belgium
        • Not yet recruiting
        • Hopital Universitaire de Bruxelles
        • Contact:
          • Thierry ROUMEGUERE, Pr
  • France
      • Angers, France, 49100
        • Recruiting
        • CHU Angers
        • Contact:
          • Pierre BIGOT, Pr
      • Bordeaux, France, 33076
        • Recruiting
        • Chu Bordeaux
        • Contact:
          • Jean-Christophe BERNHARD, Pr
      • Bordeaux, France
        • Recruiting
        • Clinique TIVOLI-DUCOS
        • Contact:
          • Clément MICHIELS, Dr
      • Cabestany, France
        • Recruiting
        • Polyclinique Médipôle Saint-Roch_Cabestany
        • Contact:
          • Pierre GIMEL, Dr
      • Caen, France
        • Recruiting
        • CHU Caen
        • Contact:
          • Xavier TILLOU, Pr
      • Chalon-sur-Saône, France
        • Not yet recruiting
        • Centre hospitalier Chalon sur Saône
        • Contact:
          • Nicolas KOUTLIDIS, Dr
      • Clermont-Ferrand, France
        • Recruiting
        • CHU de Clermont-Ferrand
        • Contact:
          • Laurent GUY, Pr
      • Colmar, France
        • Not yet recruiting
        • Hôpitaux Civils de Colmar
        • Contact:
          • Jonathan THOUVENIN, Dr
      • Corbeil-Essonnes, France
        • Recruiting
        • Ch Sud Francilien
        • Contact:
          • Pietro GRANDE, Dr
      • Creil, France
        • Not yet recruiting
        • Groupe Hospitalier Public du Sud de l'Oise
        • Contact:
          • Fares KOSSEIFI, Dr
      • Créteil, France, 94010
        • Recruiting
        • CHU Henri Mondor - APHP
        • Contact:
          • Alexandre INGELS, Pr
      • Dijon, France
        • Recruiting
        • CHU de Dijon et CLCC Dijon
        • Contact:
          • Benjamin DELATTRE, Dr
      • Fontainebleau, France
        • Recruiting
        • CH du Sud Seine et Marne
        • Contact:
          • Karim BEN OTHMAN, Dr
      • Hénin-Beaumont, France
        • Not yet recruiting
        • Polyclinique d'Henin Beaumont
        • Contact:
          • Martin LORETTE, Dr
      • La Roche-sur-Yon, France
        • Not yet recruiting
        • Centre Hospitalier Départemental de Vendée
        • Contact:
          • Constance DEBOUDT-MACE, Dr
      • La Tronche, France, 38700
        • Recruiting
        • CHU Grenoble
        • Contact:
          • Jean-Luc DESCOTES, Pr
      • Le Mans, France
        • Recruiting
        • Pôle Santé Sud
        • Contact:
          • Olivier BELAS, Dr
      • Le Puy-en-Velay, France, 43000
        • Not yet recruiting
        • Clinique Bon Secours-ELSAN
        • Contact:
          • Marlène GUANDALINO, Dr
      • Levallois-Perret, France
        • Not yet recruiting
        • Hôpital Franco-Britannique,
        • Contact:
          • Caroline PETTENATI, Dr
      • Libourne, France
        • Recruiting
        • CH Libourne
        • Contact:
          • Benjamin ROUGET, Dr
      • Lille, France
        • Recruiting
        • Hôpital privé La Louvière
        • Contact:
          • Charles BALLEREAU, Dr
      • Lille, France, 59037
        • Recruiting
        • CHRU Lille - Centre Oscar Lambret
        • Contact:
          • Jonathan OLIVIER, Pr
      • Limoges, France, 87042
        • Recruiting
        • CHU Limoges
        • Contact:
          • Aurélien DESCAZEAUD
      • Longjumeau, France
        • Not yet recruiting
        • Clinique de l'Yvette
        • Contact:
          • Benjamin GABAY, Dr
      • Lyon, France, 69002
        • Recruiting
        • HCL Lyon
        • Contact:
          • Philippe PAPAREL, Pr
      • Marseille, France
        • Recruiting
        • APH Marseille
        • Contact:
          • Eric LECHEVALLIER, Pr
      • Marseille, France
        • Recruiting
        • Institut Paoli-Calmette
        • Contact:
          • Nicolas BRANGER, Dr
      • Meaux, France
        • Not yet recruiting
        • Grand Hôpital de l'Est Francilien
        • Contact:
          • Julien SARKIS, Dr
      • Metz, France
        • Not yet recruiting
        • Centre Hospitalier d' Annecy Genevois
        • Contact:
          • Arnoux VALENTIN, Dr
      • Mont-de-Marsan, France
        • Recruiting
        • CH Mont de Marsan
        • Contact:
          • Jean-Jacques PATARD, Pr
      • Montauban, France
        • Recruiting
        • Clinique du Pont de Chaume
        • Contact:
          • Jérôme GAS, Dr
      • Montpellier, France
        • Not yet recruiting
        • CHU de Montpellier
        • Contact:
          • Rodolphe THURET, Dr
      • Nancy, France
        • Recruiting
        • CHRU de NANCY
        • Contact:
          • Pascal ESCHWEGE, Pr
      • Nantes, France
        • Recruiting
        • Chu de Nantes
        • Contact:
          • Stéphane DE VERGIE, Dr
      • Nice, France
        • Recruiting
        • CHU de Nice
        • Contact:
          • Matthieu DURAND, Pr
      • Nice, France
        • Recruiting
        • Clinique Saint George
        • Contact:
          • Alexandre MARSAUD, Dr
      • Nîmes, France
        • Recruiting
        • CHU de Nîmes
        • Contact:
          • Alexis FONTENIL, Dr
      • Orléans, France
        • Recruiting
        • CHU d'Orléans
        • Contact:
          • Nicolas BRICHART, DR
      • Paris, France
        • Not yet recruiting
        • Hopital saint Louis
        • Contact:
          • Sonia BEBANE, Dr
      • Paris, France
        • Not yet recruiting
        • Institut Mutualiste Montsouris
        • Contact:
          • Mostefa BENNAMOUN, Dr
      • Paris, France, 75013
        • Recruiting
        • CHU Kremlin Bicêtre - APHP
        • Contact:
          • Sébastien PARIER, Dr
      • Paris, France, 75014
        • Recruiting
        • CH St Joseph
        • Contact:
          • Xavier DURAND, Pr
      • Paris, France, 75015
        • Recruiting
        • Hôpital Européen Georges Pompidou - APHP
        • Contact:
          • François AUDENET, Dr
      • Paris, France
        • Recruiting
        • Hôpital Bichat -APHP
        • Contact:
          • Evangelos Xylinas, Dr
      • Paris, France
        • Recruiting
        • Hôpital Pitié Salpétrière - APHP
        • Contact:
          • Morgan ROUPRET, Pr
      • Paris, France
        • Recruiting
        • Hôpital Cochin Port-Royal - APHP
        • Contact:
          • Julien ANRACT, Dr
      • Paris, France
        • Recruiting
        • CHU Tenon - APHP
        • Contact:
          • Olivier TRAXER, Pr
      • Plérin, France
        • Recruiting
        • Hôpital Privé Des Côtes d'Armor
        • Contact:
          • Fabien BOULIERE, Dr
      • Poitiers, France
        • Recruiting
        • CHU Poitiers
        • Contact:
          • Maxime VALLEE, Dr
      • Périgueux, France
        • Recruiting
        • Polyclinique Francheville
        • Contact:
          • Richard MALLET, Dr
      • Quincy-sous-Sénart, France
        • Recruiting
        • Hôpital Privé Claude Galien
        • Contact:
          • Julien DEFONTAINES, Dr
      • Quint-Fonsegrives, France
        • Recruiting
        • Clinique La Croix Du Sud
        • Contact:
          • Jean-Baptiste BEAUVAL, Dr
      • Reims, France
        • Recruiting
        • Chu Reims
        • Contact:
          • Charlotte JONCOUR, Dr
      • Rennes, France, 35000
        • Recruiting
        • CHU Rennes - Centre Eugène Marquis
        • Contact:
          • Karim BENSALAH, Pr
      • Rouen, France, 76031
        • Recruiting
        • CHU Rouen
        • Contact:
          • Christian PFISTER, Pr
      • Saint-Etienne, France
        • Recruiting
        • CHU St-Etienne
        • Contact:
          • Lionel BADET, Pr
      • Saint-Herblain, France
        • Recruiting
        • Clinique Santé Atlantique de Nantes
        • Contact:
          • Quentin-Come LE CLERC, Dr
      • Saint-Herblain, France
        • Recruiting
        • Clinique Urologique Nantes Atlantis
        • Contact:
          • Lionel HOQUETIS, Dr
      • Saint-Martin-d'Hères, France
        • Recruiting
        • Clinique Belledonne
        • Contact:
          • Jean-Alexandre LONG, Pr
      • Strasbourg, France, 67000
        • Recruiting
        • CHU Strasbourg
        • Contact:
          • Hervé LANG, Pr
      • Strasbourg, France
        • Recruiting
        • ICANS
        • Contact:
          • Gabriel MALOUF, Pr
      • Toulouse, France
        • Recruiting
        • Clinique Pasteur
        • Contact:
          • Julien GUILLOTREAU, Dr
      • Toulouse, France, 31059
        • Recruiting
        • CHU Toulouse - Centre Claudius Régaud
        • Contact:
          • Nicolas DOUMERC, Dr
      • Tours, France
        • Recruiting
        • CHRU Tours
        • Contact:
          • Franck BRUYERE, Pr
      • Vandœuvre-lès-Nancy, France
        • Not yet recruiting
        • Institut de Cancérologie lorraine
        • Contact:
          • Sophie MARTIN, Dr
  • French Guiana
      • Kourou, French Guiana
        • Recruiting
        • Centre Hospitalier de Kourou
        • Contact:
          • Vincent RAVERY, Pr
  • Reunion
      • Saint-Denis, Reunion
        • Not yet recruiting
        • CHU Bellepierre
        • Contact:
          • Davidson SYPRE, Dr

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients with Kidney cancer

Description

Inclusion Criteria:

  • Adult patient with kidney cancer
  • Patient with no opposition to collection of its data for the study

Exclusion Criteria: none

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Patients
Adult patients with kidney cancer
Procedure: Radical nephrectomy versus partial nephrectomy (according surgeon judgement)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Comparison of the rates of complications between radical nephrectomy and partial nephrectomy
Time Frame: At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
Operative time, ,
At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
Comparison of the rates of complications between radical nephrectomy and partial nephrectomy
Time Frame: At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
Blood loss
At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
Comparison of the rates of complications between radical nephrectomy and partial nephrectomy
Time Frame: At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
Clinical scores
At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Dosage of creatininemia to assess the renal function after surgery
Time Frame: At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
Dosage of creatininemia
At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
Dosage of MDRD GFR to assess the renal function after surgery
Time Frame: At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
Dosage of MDRD GFR
At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
Comparison of the rates of mortality between radical nephrectomy and partial nephrectomy
Time Frame: At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
Medical or surgical complication rates with Clavien's grading
At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
Comparison of the rates of mortality between radical nephrectomy and partial nephrectomy
Time Frame: At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
Medical or surgical complication rates with urinary fistula rate
At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
Comparison of the rates of mortality between radical nephrectomy and partial nephrectomy
Time Frame: At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
Medical or surgical complication rates with necessity for nephrectomy or re-exploration
At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
Safety and efficacy of medical treatment on kidney tumor size evolution
Time Frame: At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
Imaging data: tumor size evolution
At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
Safety and efficacy of medical treatment on biological parameters
Time Frame: At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
Biological parameters
At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
Progression of the tumor
Time Frame: At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
Imaging data: tumor location
At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Bordeaux

Investigators

  • Principal Investigator: Jean-Christophe BERNHARD, PHU, University Hospital, Bordeaux

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

December 1, 2011

Primary Completion (Estimated)

December 1, 2040

Study Completion (Estimated)

December 1, 2040

Study Registration Dates

First Submitted

July 12, 2016

First Submitted That Met QC Criteria

September 20, 2017

First Posted (Actual)

September 26, 2017

Study Record Updates

Last Update Posted (Actual)

May 28, 2026

Last Update Submitted That Met QC Criteria

May 27, 2026

Last Verified

September 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CHUBX 2011/38

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Kidney Cancer

Clinical Trials on Radical nephrectomy versus partial nephrectomy (according surgeon judgement)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Croatia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe